SeaStar Medical Holding マネジメント

マネジメント基準チェック /34

SeaStar Medical Holdingの CEO はEric Schlorffで、 Jul2019年に任命され、の在任期間は 5.33年です。の年間総報酬は$ 637.96Kで、 65.8%給与と34.2%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の1.12%を直接所有しており、その価値は$ 100.21K 。経営陣と取締役会の平均在任期間はそれぞれ2.3年と0.9年です。

主要情報

Eric Schlorff

最高経営責任者

US$638.0k

報酬総額

CEO給与比率	65.8%
CEO在任期間	5.3yrs
CEOの所有権	1.1%
経営陣の平均在職期間	2.3yrs
取締役会の平均在任期間	less than a year

経営陣の近況

Recent updates

CEO報酬分析

SeaStar Medical Holding の収益と比較して、Eric Schlorff の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-US$30m
Jun 30 2024	n/a	n/a	-US$33m
Mar 31 2024	n/a	n/a	-US$32m
Dec 31 2023	US$638k	US$420k	-US$26m
Sep 30 2023	n/a	n/a	-US$25m
Jun 30 2023	n/a	n/a	-US$20m
Mar 31 2023	n/a	n/a	-US$18m
Dec 31 2022	US$2m	US$320k	-US$12m
Sep 30 2022	n/a	n/a	-US$5m
Jun 30 2022	n/a	n/a	-US$4m
Mar 31 2022	n/a	n/a	-US$5m
Dec 31 2021	US$323k	US$300k	-US$5m

報酬と市場: Ericの総報酬 ($USD 637.96K ) は、 US市場 ($USD 649.63K ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Ericの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Eric Schlorff (51 yo)

5.3yrs

在職期間

US$637,960

報酬

Mr. Eric Schlorff serves as Chief Executive Officer and Executive Director of SeaStar Medical Holding Corporation since July 2019 and serves as its President. He served as Chief Operating Officer at LMF Ac...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Eric Schlorff	CEO, President & Executive Director	5.3yrs	US$637.96k	1.12% $ 100.2k
Kevin Chung	Chief Medical Officer	2.3yrs	US$495.31k	0.31% $ 28.1k
H. Humes	Co-Founder and Managing Director	29.8yrs	US$205.93k	データなし
David Green	Chief Financial Officer	less than a year	データなし	0.24% $ 21.2k
Tom Mullen	Vice President of Operations & Product Development	2.8yrs	データなし	データなし
Tim Varacek	Senior VP of Commercial & Business Operations	less than a year	データなし	データなし
Sai Iyer	Senior Vice President of Medical Affairs & Research	less than a year	データなし	データなし

2.3yrs

平均在職期間

51yo

平均年齢

経験豊富な経営陣: ICUの経営陣は経験豊富であると考えられます ( 2.3年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Eric Schlorff	CEO, President & Executive Director	5.3yrs	US$637.96k	1.12% $ 100.2k
Glenn Chertow	Member of Medical Advisory Board	no data	データなし	データなし
Ravindra Mehta	Member of Medical Advisory Board	no data	データなし	データなし
Kenneth Van Heel	Independent Director	3.8yrs	US$88.16k	0.055% $ 4.9k
Richard Barnett	Independent Chairman	3.8yrs	US$126.16k	0.079% $ 7.1k
Allan Collins	Independent Director	3.8yrs	US$80.16k	0.050% $ 4.5k
David Askenazi	Member of Scientific Advisory Board	less than a year	データなし	データなし
Ayse Akcan-Arikan	Member of Scientific Advisory Board	less than a year	データなし	データなし
Sean Bagshaw	Member of Scientific Advisory Board	less than a year	データなし	データなし
Rajit Basu	Member of Scientific Advisory Board	less than a year	データなし	データなし
Andriy Batchinsky	Member of Scientific Advisory Board	less than a year	データなし	データなし
John Neuman	Director	less than a year	データなし	データなし

0.9yrs

平均在職期間

60yo

平均年齢

経験豊富なボード: ICUの取締役会は経験豊富ではない ( 0.9年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

SeaStar Medical Holding マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

High number of new and inexperienced directors

SeaStar Medical Holding Corporation Announces Board Changes

SeaStar Medical Holding Corporation Approves Class II Director Appointments

SeaStar Medical Holding Corporation, Annual General Meeting, Jun 04, 2024

SeaStar Medical Holding Corporation Announces Chief Financial Officer Changes

SeaStar Medical Forms Scientific Advisory Board of Pediatric and Adult Clinical Experts

Recent updates

FDA Grants Breakthrough Device Designation for Seastar Medical’S Selective Cytopheretic Device for Adults Undergoing Chronic Dialysis

SeaStar Medical Holding Corporation Announces Record Monthly Enrollment Achieve in It's Pivotal Adult AKI Trial

Seastar Medical Holding Corporation Enters into Confidential Settlement Agreement and Release with Nuwellis

Seastar Medical Holding Corporation Announces Enrollment in Its Adult Acute Kidney Injury Pivotal Trial Has Exceeded the Halfway Point Toward an Interim Analysis

SeaStar Medical Holding Corporation has filed a Follow-on Equity Offering in the amount of $25 million.

Levi & Korsinsky, LLP Notifies Investors in Seastar Medical Holding Corporation of A Class Action Securities Lawsuit

SeaStar Medical Holding Corporation Announces First Pediatric Patient Treated in A Commercial Setting with FDA-Approved QUELIMMUNE Therapeutic Device

SeaStar Medical Holding Corporation has completed a Follow-on Equity Offering in the amount of $10.000007 million.

SeaStar Medical Holding Corporation has filed a Follow-on Equity Offering in the amount of $10.000007 million.

SeaStar Medical Holding Corporation has filed a Follow-on Equity Offering in the amount of $10.000007 million.

The Schall Law Firm Reminds Class Action Lawsuit Against SeaStar Medical Holding Corporation

SeaStar Medical Holding Provides Notice to the Nasdaq Stock Market Regarding its Possible Violation of Nasdaq Listing Rule 5635(d)(2)

SeaStar Medical Holding Provides Notice to the Nasdaq Stock Market Regarding its Possible Violation of Nasdaq Listing Rule 5635(d)(2)

SeaStar Medical Holding Corporation Finalizes FDA Labeling Requirement for QUELIMMUNE, Paving the Way for First Commercial Sales as Humanitarian Use Device

High number of new and inexperienced directors

SeaStar Medical Holding Announces Compliance Update with Nasdaq Listing Rule 5550(b)(2) and Nasdaq Listing Rule 5550(a)(2)

SeaStar Medical Holding Corporation Announces Board Changes

SeaStar Medical Holding Corporation Approves Class II Director Appointments

SeaStar Medical Holding Corporation, Annual General Meeting, Jun 04, 2024

SeaStar Medical Announces $3.6 Million NIH Grant Award to Study the Selective Cytopheretic Device in Adult Patients with Severe Chronic Heart Failure

SeaStar Medical Announces $3.6 Million NIH Grant Award to Study the Selective Cytopheretic Device in Adult Patients with Severe Chronic Heart Failure

SeaStar Medical Holding Corporation announced delayed annual 10-K filing

Seastar Medical Provides Updates on Enrollment of Adult Pivotal Clinical Study and Commercial Launch of Quelimmune, FDA-Approved in Pediatric Patients

FDA Grants Humanitarian Device Exemption Approval to Seastar Medical’S Selective Cytopheretic Device for Pediatric Acute Kidney Injury

SeaStar Medical Holding Receives Notification from the Nasdaq Listing Qualifications Department Regarding the Company Regains Compliance with the Market Value Rule

SeaStar Medical Holding Corporation has filed a Follow-on Equity Offering in the amount of $9 million.

SeaStar Medical Holding Corporation has filed a Follow-on Equity Offering in the amount of $9 million.

SeaStar Medical Holding Corporation has filed a Follow-on Equity Offering in the amount of $9 million.

SeaStar Medical Holding Corporation Announces Chief Financial Officer Changes

SeaStar Medical Holding Receives Non-Compliance Notice from Nasdaq

SeaStar Medical Holding Corporation Updates Subject Enrollment in its Pivotal Trial with the Selective Cytopheretic Device in Adults with Acute Kidney Injury

SeaStar Medical Holding Corporation Updates Subject Enrollment in its Pivotal Trial with the Selective Cytopheretic Device in Adults with Acute Kidney Injury

SeaStar Medical Holding Receives Notification from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market

SeaStar Medical Forms Scientific Advisory Board of Pediatric and Adult Clinical Experts

New major risk - Shareholder dilution

U.S. Food and Drug Administration Issues Approvable Letter for SeaStar Medical Holding Corporation's Selective Cytopheretic Device for Pediatric Patients

FDA Grants SeaStar Medical’s Selective Cytopheretic Device Breakthrough Device Designation for Hepatorenal Syndrome

SeaStar Medical Holding Corporation Announces Publication of Case Series of Three Critically Ill Children with Acute Kidney Injury Safely Treated with it's Selective Cytopheretic Device

SeaStar Medical Holding Corporation Enrolls First Patient in NEUTRALIZE-AKI Pivotal Clinical Trial with the Selective Cytopheretic Device in Adults with Acute Kidney Injury

Seastar Medical Holding Receives Nasdaq Staff Deficiency Letter Regarding Non-Compliance with Market Value of Listed Securities Requirements

SeaStar Medical Holding Corporation, Annual General Meeting, Jun 28, 2023

SeaStar Medical Holding Corporation Provides Regulatory Update Related to HDE Application for Pediatric Selective Cytopheretic Device

SeaStar Medical Announces Details of the Selective Cytopheretic Device Pivotal Study in Critically ill Adults with Acute Kidney Injury

Seastar Medical Receives FDA Approval to Begin Study with Selective Cytopheretic Device to Reduce Hyperinflammation in Adults with Acute Kidney Injury

SeaStar Medical Holding Corporation Submits Investigational Device Exemption Application to FDA to Study a Novel Therapy to Reduce Hyperinflammation in Adult Acute Kidney Injury Patients

High number of new directors

Seastar Medical Appoints Rick Barnett as Chairman of the Board of Directors

No independent directors

SeaStar Medical Announces Positive Interim Safety Findings from Ongoing Study Evaluating the Selective Cytopheretic Device (SCD) in Children

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /34